Insulet Corporation (PODD)
| Market Cap | 18.70B |
| Revenue (ttm) | 1.98B |
| Net Income (ttm) | 420.90M |
| Shares Out | 70.14M |
| EPS (ttm) | 5.74 |
| PE Ratio | 46.48 |
| Forward PE | 72.35 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,342,506 |
| Open | 256.56 |
| Previous Close | 256.56 |
| Day's Range | 256.56 - 270.70 |
| 52-Week Range | 160.19 - 279.77 |
| Beta | 1.22 |
| Analysts | Buy |
| Price Target | 265.81 (-0.29%) |
| Earnings Date | Feb 20, 2025 |
About PODD
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company’s Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch... [Read more]
Financial Performance
In 2023, Insulet's revenue was $1.70 billion, an increase of 30.02% compared to the previous year's $1.31 billion. Earnings were $206.30 million, an increase of 4384.78%.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for PODD stock is "Buy." The 12-month stock price forecast is $265.81, which is a decrease of -0.29% from the latest price.
News
Insulet wins $452 mln US verdict against EOFlow in insulin pump secrets case
Medical device maker Insulet convinced a jury that Korean rival EOFlow owes it $452 million in damages for stealing trade secrets related to insulin pumps, according to a verdict made public in Massac...
Insulet Successfully Defends its Intellectual Property Against EOFlow Co. in U.S. District Court
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, announced that it...
Insulet Corporation: Significant Opportunities, Significant Threats - I'm On The Sidelines
Insulet's stock has surged over 50% in six months due to strong Q3 earnings and expanded market potential with Omnipod 5's approval for Type 2 diabetes. Despite impressive growth, high market expectat...
Insulet Announces Omnipod® 5 System is Now Compatible with Abbott's FreeStyle Libre 2 Plus Sensor in the U.S.
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced t...
Insulet to Present at Upcoming Investor Conferences
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management ...
Insulet CEO on earnings, GLP-1 and election impact
Jim Hollingshead, Insulet CEO, joins 'Closing Bell: Overtime' to discuss the Insulet earnings, Apple blood sugar testing app and more.
Buy, Sell, Or Hold Insulet (PODD) Stock?
Insulet stock (NASDAQ: PODD) surged nearly 10% on Friday, November 8, after the company posted an upbeat Q3 and raised its sales outlook. It reported sales of $544 million and adjusted earnings of $0....
Top 4 Health Care Stocks That May Plunge This Quarter
As of Nov. 11, 2024, four stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Insulet Corporation (PODD) Q3 2024 Earnings Call Transcript
Insulet Corporation (PODD) Q3 2024 Earnings Call Transcript
Insulet raises annual revenue forecast on strong demand for insulin pumps
Insulet raised its annual revenue growth forecast on Thursday, banking on strong demand for its wearable insulin pumps.
Insulet Reports Third Quarter 2024 Revenue Increase of 26% Year-Over-Year (25% Constant Currency1)
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced f...
Insulet Announces Array of Activities to Support National Diabetes Awareness Month and World Diabetes Day in November
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced p...
Omnipod® 5 App for iPhone® Now Fully Available in the United States
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced t...
National Campaign Launches to Combat Diabetes Stigma Using Comedy
SAN FRANCISCO , Oct. 10, 2024 /PRNewswire/ -- The Spoonful of Laughter campaign is a national initiative using comedy to educate about diabetes, counter harmful stereotypes and stigma, and amplify aut...
Insulet to Announce Third Quarter 2024 Financial Results on November 7, 2024
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced p...
Upstart, Insulet And 2 Other Stocks Executives Are Selling
The Nasdaq 100 closed higher by over 400 points during Wednesday's session. Investors, meanwhile, focused on some notable insider trades.
What Helped Insulet Stock Gain 10% This Week?
Insulet stock (NASDAQ: PODD) currently trades around $200 per share, about 35% lower than the levels of over $300 seen in early November 2021. In comparison, its peer – DexCom stock – is down 55% over...
S&P 500 Gains and Losses Today: Medical Device Makers ResMed, Insulet Lead Index
Major U.S. equities indexes ticked higher ahead of a potentially consequential earnings report from semiconductor giant Nvidia (NVDA) as well as key inflation and economic data set for release later i...
This Healthcare Stock Is the Best Performer in the S&P 500 Tuesday
Insulet got a key FDA approval for an insulin delivery system.
Omnipod® 5 Automated Insulin Delivery System is now FDA-cleared for People with Type 2 Diabetes
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced i...
These Two Stocks Plunged After Eli Lilly Drug Study Showed Diabetes Promise
Shares of Insulet (PODD) and DexCom (DXCM), two companies that provide medical devices for patients managing diabetes, tumbled Tuesday after a study showed that a popular drug made by Eli Lilly (LLY) ...
Insulet Celebrates Grand Opening of 400,000-square-foot Manufacturing Facility in Malaysia
ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today hosted a gr...
Insulin Pump Maker Insulet's Stock Slumps on User Growth Concerns
Shares of Insulet (PODD) suffered the heaviest losses of any S&P 500 stock on Friday, dropping 8.8% after the maker of insulin management devices suggested new user growth could be lower than previous...
Insulet Is the Worst Stock in S&P 500 Today, Despite Solid Earnings. Here's Why.
The automated insulin technology developer stock is on track for its largest percentage decline since February.
Insulin Pump Maker Insulet's Growth Catalysts Set to Boost Revenue in 2025: Analyst
Insulin device maker Insulet Corporation PODD reported a second-quarter adjusted EPS of $0.55 on Thursday, missing the consensus estimate of $0.56. It reported an EPS of $0.38 a year ago.